Treating metastatic cancer and model systems for metastatic disease
The present invention relates to methods and compositions for inhibiting metastatic spread of cancer and/or inhibiting progression of pre-existing metastatic disease in a subject using L1CAM inhibition.
1. A method of reducing the risk, in a subject who has received treatment for a primary cancer, of metastatic spread of the primary cancer, comprising administering to the subject a therapeutic amount of a L1CAM inhibitor, wherein the L1CAM inhibitor is administered:
(a) at least one month after a course of chemotherapy, targeted therapy, immunotherapy and/or radiotherapy of the primary cancer is completed;
(b) after the subject has achieved remission of the primary cancer; or
(c) after a surgical excision of the primary cancer or a metastasis has been completed.
2. The method of claim 1 , where the L1CAM inhibitor is administered in a maintenance regimen.
3. The method of claim 2 , wherein the L1CAM inhibitor is administered at least once a week, at least once a month, at least once every two months, at least once every three months, or at least once every six months.
4. The method of claim 1 , wherein the L1CAM inhibitor is an immunoglobulin.
5. The method of claim 4 , wherein the L1CAM inhibitor is an immunoglobulin bispecific for L1CAM and CD133 or an immunoglobulin bispecific for L1CAM and CD44.
6. The method of claim 1 , wherein the L 1 CAM inhibitor is an interfering RNA or an antisense RNA.
7. The method of claim 1 , wherein the primary cancer is breast cancer, lung cancer, renal cancer, or colorectal cancer.
8. A method of inhibiting metastatic spread of a primary cancer in a subject who has received treatment for the primary cancer, comprising administering to the subject a therapeutic amount of a L1CAM inhibitor, wherein the L1CAM inhibitor is administered:
(a) at least one month after a course of chemotherapy, targeted therapy, immunotherapy and/or radiotherapy of the primary cancer is completed;
(b) after the subject has achieved remission of the primary cancer; or
(c) after a surgical excision of the primary cancer or a metastasis has been completed.
9. A method of inhibiting progression of metastatic disease in a subject who has received treatment for the primary cancer, comprising administering to the subject a therapeutic amount of a L1CAM inhibitor, wherein the L1CAM inhibitor is administered:
(a) at least one month after a course of chemotherapy, targeted therapy, immunotherapy and/or radiotherapy of the primary cancer is completed;
(b) after the subject has achieved remission of the primary cancer; or
(c) after a surgical excision of the primary cancer or a metastasis has been completed.
10. The method of claim 8 , wherein the L1CAM inhibitor is administered at least once a week, at least once a month, at least once every two months, at least once every three months, or at least once every six months.
11. The method of claim 8 , wherein the L1CAM inhibitor is an immunoglobulin.
12. The method of claim 8 , wherein the primary cancer is breast cancer, lung cancer, renal cancer, or colorectal cancer.
13. The method of claim 9 , wherein the L1CAM inhibitor is administered at least once a week, at least once a month, at least once every two months, at least once every three months, or at least once every six months.
14. The method of claim 9 , wherein the L1CAM inhibitor is an immunoglobulin.
15. The method of claim 9 , wherein the primary cancer is breast cancer, lung cancer, renal cancer, or colorectal cancer.